DOCSLIB.ORG

WO 2012/113835 Al 30 August 2012 (30.08.2012) P O P C T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WO 2012/113835 Al 30 August 2012 (30.08.2012) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/113835 Al 30 August 2012 (30.08.2012) P O P C T (51) International Patent Classification: LOPEZ, Daniela Melanie [VE/FR]; Universite Bordeaux A61K 31/357 (2006.01) A61P 19/10 (2006.01) 1 - Institut des Sciences Moleculaires (CNRS-UMR 5255) A61P 35/00 (2006.01) 2 rue Robert Escarpit, F-33607 Pessac Cedex (FR). (21) International Application Number: (74) Agents: BLOT, Philippe et al; Cabinet LAVOTX, 2, place PCT/EP2012/053017 d'Estienne d'Orves, F-75009 Paris (FR). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 22 February 2012 (22.02.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (25) Filing Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (26) Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 11305186.6 22 February 201 1 (22.02.201 1) EP MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (71) Applicant (for all designated States except US): INSTI- OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, TUT NATIONAL DE LA SANTE ET DE LA SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, RECHERCHE MEDICALE (INSERM) [FR/FR]; 101, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Rue de Tolbiac, F-75013 Paris (FR). (84) Designated States (unless otherwise indicated, for every (72) Inventors; and kind of regional protection available): ARIPO (BW, GH, (75) Inventors/Applicants (for US only): QUIDEAU, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, Stephane [FR/FR]; Universite Bordeaux 1 - Institut des UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, Sciences Moleculaires (CNRS-UMR 5255) 2 rue Robert TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Escarpit, F-33607 Pessac Cedex (FR). GENOT, Elisabeth DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, [FR/FR]; INSERM U1053 et Institut Europeen de Chimie LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, et Biologie 2 rue Robert Escarpit, F-33607 Pessac Cedex SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). (FR). SALTEL, Frederic [FR/FR]; INSERM U1053 et In stitut Europeen de Chimie et Biologie 2 rue Robert E s Published: carpit, F-33607 Pessac Cedex (FR). DOUAT-CASASSUS, — with international search report (Art. 21(3)) Celine [FR/FR]; Universite Bordeaux 1 - Institut des Sci ences Moleculaires (CNRS-UMR 5255) 2 rue Robert Es carpit, F-33607 Pessac Cedex (FR). DELANNOY (54) Title: C-GLUCOSIDIC ELLAGITANNIN COMPOUNDS FOR USE FOR ALTERING THE SUPRAMOLECULAR AR RANGEMENT OF ACTIN AND FOR THE TREATMENT OF OSTEOPOROSIS, CANCER, BACTERIAL INFECTION AND VIRAL INFECTION FIGA (57) Abstract: The present invention concerns a C-glucosidic ellagitannin compound or a metabolite thereof for use for altering the supramolecular arrangement of actin in an individual suffering from osteoporosis, cancer, bacterial infection, or viral infection. It also pertains to pharmaceutical compositions comprising a C-glucosidic ellagitannin compound and/or metabolites thereof and one or more physiologically acceptable carriers. It finally concerns a C-glucosidic ellagitannin compound or a metabolite thereof, option - ally detectably labeled, for in vitro use as a tool for studying cellular mechanisms involving actin, or for detecting F-actin in a cell. C-GLUCOSIDIC ELLAGITANNIN COMPOUNDS FOR USE FOR ALTERING THE SUPRAMOLECULAR ARRANGEMENT OF ACTIN AND FOR THE TREATMENT OF OSTEOPOROSIS, CANCER, BACTERIAL INFECTION AND VIRAL INFECTION The present invention concerns a C-glucosidic ellagitannin compound, or a 5 metabolite, for use for altering the supramolecular arrangement of actin in an individual in need thereof. It also pertains to pharmaceutical compositions comprising a C-glucosidic ellagitannin compound and/or metabolites thereof and one or more physiologically acceptable carriers. It finally concerns a C-glucosidic ellagitannin compound or a metabolite thereof, optionally detectably labeled, for in vitro use as a tool for studying 10 cellular mechanisms involving actin, or for detecting F-actin in a cell. BACKGROUND OF THE INVENTION The actin cytoskeleton and cancer 15 Cancer is an unregulated proliferation of cells due to loss of normal controls, resulting in unregulated growth, lack of differentiation, local tissue invasion, and often, metastasis. Cancer can develop in any tissue or organ at any age. Many cancers are curable if detected at an early stage, and long-term remission is often possible in later stages. However, cure is not always possible and is not attempted in some advanced 0 cases. The development of drugs effective against cancer and having limited toxic side effects thus remains a critical need. As a tumor grows, nutrients are provided by direct diffusion from the circulation. As tumor volume increases, tumor angiogenesis factors are produced to promote formation of the vascular supply required for further tumor growth. 5 Almost from inception, a tumor may shed cells into the circulation. Although most circulating tumor cells die as a result of intravascular trauma, an occasional cell may adhere to the vascular endothelium and penetrate into surrounding tissues, generating independent tumors (metastases) at distant sites. Metastatic tumors grow in much the same manner as primary tumors and may subsequently give rise to other metastases. 0 Experiments suggest that through random mutation, a subset of cells in the primary tumor may acquire the ability to invade and migrate to distant sites, resulting in metastasis. In non cancer cells, adhesion to the extracellular matrix and to neighbouring cells 5 plays a central role in the control of cell survival, growth, differentiation, motility, and tissue integrity. Upon oncogenic transformation, profound changes occur in the organization of the actin cytoskeleton, manifesting on cell morphology and motility. Increased proliferation, a hallmark of cancer cells, is highly dependent upon actin dynamics and cell adhesion. Adhesive interactions involve specialized transmembrane receptors that are linked to the cytoskeleton through junctional plaque proteins. The synthesis of several actin-binding proteins, including a-actinin, vinculin, tropomyosin and profilin, is down- regulated in transformed cells and overexpressing these proteins in tumor cells suppresses the transformed phenotype, which allows them to be considered as tumor suppressors. The actin cytoskeleton and osteoporosis Osteoporosis is a progressive metabolic bone disease that decreases bone density with deterioration of bone structure. Skeletal weakness leads to fractures with minor or inapparent trauma, particularly in the thoracic and lumbar spine, wrist, and hip. Acute or chronic back pain is common. Prevention and treatment involve calcium and vitamin D supplements, exercises to maximize bone and muscle strength and minimize the risk of falls, and drug therapy to preserve bone mass or stimulate new bone formation. Normally, bone formation and resorption are closely coupled. Osteoblasts (cells that make the organic matrix of bone and then mineralize bone) and osteoclasts (cells that resorb bone) are regulated by parathyroid hormone (PTH), calcitonin, estrogen, vitamin D, various cytokines, and other local factors such as prostaglandins. Peak bone mass in men and women occurs by the mid 20s. Bone mass plateaus for about 10 yr, during which time bone formation approximately equals bone resorption. After this, bone loss occurs at a rate of about 0.3 to 0.5% per year. Beginning with menopause, bone loss accelerates in women to about 3 to 5% per year for about 5 to 7 year. The major mechanism is increased bone resorption, which results in decreased bone mass and microarchitectural deterioration, even though other mechanisms also contribute to osteoporosis. The mechanisms of bone loss may involve local changes in the production of bone-resorbing cytokines (such as increases in cytokines that stimulate bone resorption), impaired formation response during bone remodeling (probably caused by age-related decline in the number and activity of osteoblasts), and other factors such as a decline in local and systemic growth factors. The goals of treatment against osteoporosis are to preserve bone mass, prevent fractures, decrease pain, and maintain function. The rate of bone loss can be slowed with drugs (e.g. bisphosphonates or other anti-resorptive drugs) and, when possible, modification of risk factors. Calcium and vitamin D intake and physical activity must be adequate for drug treatment to be effective. Bisphosphonates are first-line drug therapy. By inhibiting bone resorption, bisphosphonates preserve bone mass and can decrease vertebral and hip fractures by 50%. All increase bone mineral density and decrease risk of at least vertebral fractures. However, osteonecrosis of the jaw has been associated with use of bisphosphonates. Risk factors also include bisphosphonate use and cancer. Bisphosphonates may further be associated with atrial fibrillation, but the mechanism is not clear and there has been no association with increased cardiovascular mortality. Estrogen can preserve bone density and prevent fractures. Most effective if started within 4 to 6 yr of menopause, estrogen may slow bone loss and possibly reduce fractures even when started much later. However, use of estrogen increases the risk of thromboembolism and endometrial cancer and may increase the risk of breast cancer. The risk of endometrial cancer can be reduced in women with an intact uterus by taking a progestin with estrogen. However, taking a combination of a progestin and estrogen increases the risk of breast cancer, coronary artery disease, stroke, and biliary disease.
Load more

Recommended publications
  • Intereferents in Condensed Tannins Quantification by the Vanillin Assay
    INTEREFERENTS IN CONDENSED TANNINS QUANTIFICATION BY THE VANILLIN ASSAY IOANNA MAVRIKOU Dissertação para obtenção do Grau de Mestre em Vinifera EuroMaster – European Master of Sciences of Viticulture and Oenology Orientador: Professor Jorge Ricardo da Silva Júri: Presidente: Olga Laureano, Investigadora Coordenadora, UTL/ISA Vogais: - Antonio Morata, Professor, Universidad Politecnica de Madrid - Jorge Ricardo da Silva, Professor, UTL/ISA Lisboa, 2012 Acknowledgments First and foremost, I would like to thank the Vinifera EuroMaster consortium for giving me the opportunity to participate in the M.Sc. of Viticulture and Enology. Moreover, I would like to express my appreciation to the leading universities and the professors from all around the world for sharing their scientific knowledge and experiences with us and improving day by day the program through mobility. Furthermore, I would like to thank the ISA/UTL University of Lisbon and the personnel working in the laboratory of Enology for providing me with tools, help and a great working environment during the experimental period of this thesis. Special acknowledge to my Professor Jorge Ricardo Da Silva for tutoring me throughout my experiment, but also for the chance to think freely and go deeper to the field of phenols. Last but most important, I would like to extend my special thanks to my family and friends for being a true support and inspiration in every doubt and decision. 1 UTL/ISA University of Lisbon “Vinifera Euromaster” European Master of Science in Viticulture&Oenology Ioanna Mavrikou: Inteferents in condensed tannins quantification with vanillin assay MSc Thesis: 67 pages Key Words: Proanthocyanidins; Interference substances; Phenols; Vanillin assay Abstract Different methods have been established in order to perform accurately the quantification of the condensed tannins in various plant products and beverages.
    [Show full text]
  • Glucosidase Inhibition and Antioxidant Activity of an Oenological Commercial Tannin
    Food Chemistry 215 (2017) 50–60 Contents lists available at ScienceDirect Food Chemistry journal homepage: www.elsevier.com/locate/foodchem a-Glucosidase inhibition and antioxidant activity of an oenological commercial tannin. Extraction, fractionation and analysis by HPLC/ESI-MS/MS and 1H NMR ⇑ ⇑ Vera Muccilli , Nunzio Cardullo, Carmela Spatafora , Vincenzo Cunsolo, Corrado Tringali Dipartimento di Scienze Chimiche, Università degli Studi di Catania, V.le A. Doria 6, 95125 Catania, Italy article info abstract Article history: Two batches of the oenological tannin Tan’Activ R, (toasted oak wood – Quercus robur), were extracted Received 6 November 2015 with ethanol. A fractionation on XAD-16 afforded four fractions for each extract. Extracts and fractions Received in revised form 27 May 2016 were evaluated for antioxidant activity (DPPH), polyphenol content (GAE) and yeast a-glucosidase inhi- Accepted 25 July 2016 bitory activity. Comparable results were obtained for both columns, fractions X1B and X2B showing the Available online 25 July 2016 highest antioxidant activity. Fractions X1C and X2C notably inhibited a-glucosidase, with IC50 = 9.89 and 8.05 lg/mL, respectively. Fractions were subjected to HPLC/ESI-MS/MS and 1H NMR analysis. The main Keywords: phenolic constituents of both X1B and X2B were a monogalloylglucose isomer (1), a HHDP-glucose Plant polyphenols isomer (2), castalin (3) gallic acid (4), vescalagin (5), and grandinin (or its isomer roburin E, 6). X1C Oenological tannins Quercus robur and X2C showed a complex composition, including non-phenolic constituents. Fractionation of X2C gave a l a-Glucosidase inhibition a subfraction, with enhanced -glucosidase inhibitory activity (IC50 = 6.15 g/mL), with castalagin (7)as HPLC/ESI-MS/MS the main constituent.
    [Show full text]
  • Universidade Federal Do Rio De Janeiro Kim Ohanna
    UNIVERSIDADE FEDERAL DO RIO DE JANEIRO KIM OHANNA PIMENTA INADA EFFECT OF TECHNOLOGICAL PROCESSES ON PHENOLIC COMPOUNDS CONTENTS OF JABUTICABA (MYRCIARIA JABOTICABA) PEEL AND SEED AND INVESTIGATION OF THEIR ELLAGITANNINS METABOLISM IN HUMANS. RIO DE JANEIRO 2018 Kim Ohanna Pimenta Inada EFFECT OF TECHNOLOGICAL PROCESSES ON PHENOLIC COMPOUNDS CONTENTS OF JABUTICABA (MYRCIARIA JABOTICABA) PEEL AND SEED AND INVESTIGATION OF THEIR ELLAGITANNINS METABOLISM IN HUMANS. Tese de Doutorado apresentada ao Programa de Pós-Graduação em Ciências de Alimentos, Universidade Federal do Rio de Janeiro, como requisito parcial à obtenção do título de Doutor em Ciências de Alimentos Orientadores: Profa. Dra. Mariana Costa Monteiro Prof. Dr. Daniel Perrone Moreira RIO DE JANEIRO 2018 DEDICATION À minha família e às pessoas maravilhosas que apareceram na minha vida. ACKNOWLEDGMENTS Primeiramente, gostaria de agradecer a Deus por ter me dado forças para não desistir e por ter colocado na minha vida “pessoas-anjo”, que me ajudaram e me apoiaram até nos momentos em que eu achava que ia dar tudo errado. Aos meus pais Beth e Miti. Eles não mediram esforços para que eu pudesse receber uma boa educação e para que eu fosse feliz. Logo no início da graduação, a situação financeira ficou bem apertada, mas eles continuaram fazendo de tudo para me ajudar. Foram milhares de favores prestados, marmitas e caronas. Meu pai diz que fez anos de curso de inglês e espanhol, porque passou anos acordando cedo no sábado só para me levar no curso que eu fazia no Fundão. Tinha dia que eu saía do curso morta de fome e quando eu entrava no carro, tinha uma marmita com almoço, com direito até a garrafa de suco.
    [Show full text]
  • Exploring New Antioxidant and Mineral Compounds from Nymphaea Alba Wild-Grown in Danube Delta Biosphere
    molecules Article Exploring New Antioxidant and Mineral Compounds from Nymphaea alba Wild-Grown in Danube Delta Biosphere Mihaela Cudalbeanu 1, Ioana Otilia Ghinea 1, Bianca Furdui 1, Durand Dah-Nouvlessounon 2, Robert Raclea 3, Teodor Costache 4 ID , Iulia Elena Cucolea 4, Florentina Urlan 4 and Rodica Mihaela Dinica 1,* 1 Faculty of Sciences and Environment, Department of Chemistry Physical and Environment, “Dunarea de Jos” University of Galati, 111 Domneasca Street, 800201 Galati, Romania; [email protected] (M.C.); [email protected] (I.O.G.); [email protected] (B.F.) 2 Faculty of Sciences and Techniques, Department of Biochemistry and Cell Biology, Laboratory of Biology and Molecular Typing in Microbiology, University of Abomey-Calavi, Cotonou 05BP1604, Benin; [email protected] 3 Imperial College London, Faculty of Natural Sciences, Department of Chemistry, London SW7 2AZ, UK; [email protected] 4 Research Center for Instrumental Analysis SCIENT, 1E Petre Ispirescu Street, 077167 Tancabesti, Ilfov, Romania; [email protected] (T.C.); [email protected] (I.E.C.); fl[email protected] (F.U.) * Correspondence: [email protected] Received: 26 April 2018; Accepted: 18 May 2018; Published: 23 May 2018 Abstract: Nymphaea alba is an aquatic flowering plant from the Nymphaeaceae family that has been used for hundreds of years in traditional herbal medicine. The plant is characterized by different phytochemicals, depending on the geographical location. Herein, we have carried out, for the first time, the separation and HPLC-MS/MS identification of some antioxidant compounds, such as polyphenols and flavonoids from N. alba extracts from the Danube Delta Biosphere, and investigated their possible antiradical properties.
    [Show full text]
  • Print This Article
    PEER-REVIEWED ARTICLE bioresources.com Analysis of Valonia Oak (Quercus aegylops) Acorn Tannin and Wood Adhesives Application Soliman Abdalla,a,* Antonio Pizzi,a,b,* Fatimah Bahabri,c and Aysha Ganash d The coupling of matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry with 13C nuclear magnetic resonance (NMR) is a suitable method for examining the composition of hydrolysable tannins and has been applied to the investigation of valonia oak (Quercus aegylops) acorn tannin extract. Such methods can determine the extract’s structural aspects and other characteristics. It was determined that valonia oak acorn tannin extract is composed of mainly pentagalloylglucose structures; their rearrangement structures, vescalagin/castalagin (with linkages to flavogallonic acid) and vescalin/castalin; ellagic acid and vescavaloneic/castavaloneic acid; and free gallic acid and glucose. Traces of catechin gallate were also observed in this tannin extract. The tannin from acorns of valonia oak was used to substitute up to 50% of the phenol used in the preparation of phenolic resins as adhesives for wood particleboard. These phenol-tannin-formaldehyde resins showed comparable performance to phenol-formaldehyde resins. Keywords: MALDI; Mass spectrometry; 13C NMR; Hydrolysable tannins; Structure; Structural composition; Oligomer distribution; Wood panels; Phenolic adhesives Contact information: a: Department of Physics, Faculty of Science, King Abdulaziz University Jeddah, P.O. Box 80203, Jeddah 21589, Saudi Arabia; b:
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,772,352 B1 Huang Et Al
    US008772352B1 (12) United States Patent (10) Patent No.: US 8,772,352 B1 Huang et al. (45) Date of Patent: *Jul. 8, 2014 (54) METHODS OF TREATING (52) U.S. Cl. GASTRONTESTINAL SPASMS INA CPC ............... A61K 33/40 (2013.01); A61K 36/185 SUBJECT HAVING COLORECTAL CANCER (2013.01); A61 K3I/7028 (2013.01); A61 K 31/192 (2013.01); A61K 36/82 (2013.01) (71) Applicant: LiveLeaf, Inc., San Carlos, CA (US) USPC .......................................... 514/714; 424/1.73 (58) Field of Classification Search (72) Inventors: Alexander L. Huang, Menlo Park, CA None (US); Gin Wu, San Rafael, CA (US) See application file for complete search history. (73) Assignee: Liveleaf, Inc., San Carlos, CA (US) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this U.S. PATENT DOCUMENTS patent is extended or adjusted under 35 1844,018 A 2f1932 Sailer U.S.C. 154(b) by 0 days. 1,891,149 A 12/1932 Elger This patent is Subject to a terminal dis 1965,458 A 7/1934 Elger claimer. (Continued) (21) Appl. No.: 14/222,605 FOREIGN PATENT DOCUMENTS CN 2009.10167930.5 10/2009 (22) Filed: Mar 22, 2014 EP O3901.07 10, 1990 Related U.S. Application Data (Continued) (63) Continuation of application No. 14/173,079, filed on OTHER PUBLICATIONS Feb. 5, 2014, which is a continuation of application Related U.S. Appl. No. 13/726, 180, filed Dec. 23, 2012, Huang,et al. No. 14/142,895, filed on Dec. 29, 2013, now Pat. No. 8,716.353, which is a continuation of application No.
    [Show full text]
  • WO 2018/002916 Al O
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/002916 Al 04 January 2018 (04.01.2018) W !P O PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C08F2/32 (2006.01) C08J 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, C08G 18/08 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/IL20 17/050706 HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (22) International Filing Date: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 26 June 2017 (26.06.2017) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 246468 26 June 2016 (26.06.2016) IL kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (71) Applicant: TECHNION RESEARCH & DEVEL¬ UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, OPMENT FOUNDATION LIMITED [IL/IL]; Senate TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, House, Technion City, 3200004 Haifa (IL).
    [Show full text]
  • Profile of Bioactive Compounds in Nymphaea Alba L. Leaves Growing
    Bakr et al. BMC Complementary and Alternative Medicine (2017) 17:52 DOI 10.1186/s12906-017-1561-2 RESEARCH ARTICLE Open Access Profile of bioactive compounds in Nymphaea alba L. leaves growing in Egypt: hepatoprotective, antioxidant and anti-inflammatory activity Riham Omar Bakr1*, Mona Mohamed El-Naa2, Soumaya Saad Zaghloul1 and Mahmoud Mohamed Omar3,4 Abstract Background: Nymphaea alba L. represents an interesting field of study. Flowers have antioxidant and hepatoprotective effects, rhizomes constituents showed cytotoxic activity against liver cell carcinoma, while several Nymphaea species have been reported for their hepatoprotective effects. Leaves of N. alba have not been studied before. Therefore, in this study, in-depth characterization of the leaf phytoconstituents as well as its antioxidant and hepatoprotective activities have been performed where N. alba leaf extract was evaluated as a possible therapeutic alternative in hepatic disorders. Methods: The aqueous ethanolic extract (AEE, 70%) was investigated for its polyphenolic content identified by high-resolution electrospray ionisation mass spectrometry (HRESI-MS/MS), while the petroleum ether fraction was saponified, and the lipid profile was analysed using gas liquid chromatography (GLC) analysis and compared with reference standards. The hepatoprotective activity of two doses of the extract (100 and 200 mg/kg; P.O.) for 5 days was evaluated against CCl4-induced hepatotoxicity in male Wistar albino rats, incomparisonwithsilymarin.Liverfunctiontests; aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma glutamyl transpeptidase (GGT) and total bilirubin were performed. Oxidative stress parameters; malondialdehyde (MDA), reduced glutathione (GSH), catalase (CAT), superoxide dismutase (SOD), total antioxidant capacity (TAC) as well as inflammatory mediator; tumour necrosis factor (TNF)-α were detected in the liver homogenate.
    [Show full text]
  • Compositions and Methods for Improving
    (19) TZZ¥ ZZ_T (11) EP 3 278 800 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/352 (2006.01) A61K 36/00 (2006.01) 10.04.2019 Bulletin 2019/15 A61K 36/185 (2006.01) (21) Application number: 17186188.3 (22) Date of filing: 23.12.2011 (54) COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING MUSCLE-RELATED PATHOLOGICAL CONDITIONS ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERBESSERUNG DER MITOCHONDRIENFUNKTION UND BEHANDLUNG VON PATHOLOGISCHEN MUSKULÄREN ERKRANKUNGEN COMPOSITIONS ET PROCÉDÉS POUR AMÉLIORER LA FONCTION MITOCHONDRIALE ET TRAITER DES CONDITIONS PATHOLOGIQUES MUSCULAIRES (84) Designated Contracting States: • PIRINEN, Eija AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 00240 Helsinki (FI) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •THOMAS,Charles PL PT RO RS SE SI SK SM TR 21000 Dijon (FR) • HOUTKOOPER, Richardus (30) Priority: 23.12.2010 US 201061426957 P Weesp (NL) • BLANCO-BOSE, William (43) Date of publication of application: CH-1090 La Croix (Lutry) (CH) 07.02.2018 Bulletin 2018/06 • MOUCHIROUD, Laurent 1110 Morges (CH) (60) Divisional application: • GENOUX, David 18166896.3 / 3 372 228 CH-1000 Lausanne (CH) 18166897.1 / 3 369 420 (74) Representative: Abel & Imray (62) Document number(s) of the earlier application(s) in Westpoint Building accordance with Art. 76 EPC: James Street West 11808119.9 / 2 654 461 Bath BA1 2DA (GB) (73) Proprietor: Amazentis SA (56) References cited: 1015 Lausanne (CH) US-A1- 2003 078 212 US-A1- 2009 326 057 (72) Inventors: • JUSTIN R.
    [Show full text]
  • Traditional Applications of Tannin Rich Extracts Supported by Scientific Data: Chemical Composition, Bioavailability and Bioaccessibility
    foods Review Traditional Applications of Tannin Rich Extracts Supported by Scientific Data: Chemical Composition, Bioavailability and Bioaccessibility Maria Fraga-Corral 1,2 , Paz Otero 1,3 , Lucia Cassani 1,4 , Javier Echave 1 , Paula Garcia-Oliveira 1,2 , Maria Carpena 1 , Franklin Chamorro 1, Catarina Lourenço-Lopes 1, Miguel A. Prieto 1,* and Jesus Simal-Gandara 1,* 1 Nutrition and Bromatology Group, Analytical and Food Chemistry Department, Faculty of Food Science and Technology, Ourense Campus, University of Vigo, 32004 Ourense, Spain; [email protected] (M.F.-C.); [email protected] (P.O.); [email protected] (L.C.); [email protected] (J.E.); [email protected] (P.G.-O.); [email protected] (M.C.); [email protected] (F.C.); [email protected] (C.L.-L.) 2 Centro de Investigação de Montanha (CIMO), Campus de Santa Apolonia, Instituto Politécnico de Bragança, 5300-253 Bragança, Portugal 3 Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Veterinary, University of Santiago of Compostela, 27002 Lugo, Spain 4 Research Group of Food Engineering, Faculty of Engineering, National University of Mar del Plata, Mar del Plata RA7600, Argentina * Correspondence: [email protected] (M.A.P.); [email protected] (J.S.-G.) Abstract: Tannins are polyphenolic compounds historically utilized in textile and adhesive industries, Citation: Fraga-Corral, M.; Otero, P.; but also in traditional human and animal medicines or foodstuffs. Since 20th-century, advances in Cassani, L.; Echave, J.; analytical chemistry have allowed disclosure of the chemical nature of these molecules. The chemical Garcia-Oliveira, P.; Carpena, M.; profile of extracts obtained from previously selected species was investigated to try to establish a Chamorro, F.; Lourenço-Lopes, C.; bridge between traditional background and scientific data.
    [Show full text]
  • The Metabolite Urolithin-A Ameliorates Oxidative Stress in Neuro-2A Cells, Becoming a Potential Neuroprotective Agent
    antioxidants Article The Metabolite Urolithin-A Ameliorates Oxidative Stress in Neuro-2a Cells, Becoming a Potential Neuroprotective Agent Guillermo Cásedas 1, Francisco Les 1,2 , Carmen Choya-Foces 3, Martín Hugo 3 and Víctor López 1,2,* 1 Facultad de Ciencias de la Salud, Universidad San Jorge, 50830 Villanueva de Gállego (Zaragoza), Spain; [email protected] (G.C.); fl[email protected] (F.L.) 2 Instituto Agroalimentario de Aragón-IA2 (CITA-Universidad de Zaragoza), 50059 Zaragoza, Spain 3 Unidad de Investigación, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria Princesa (IIS-IP), E-28009 Madrid, Spain; [email protected] (C.C.-F.); [email protected] (M.H.) * Correspondence: [email protected] Received: 7 February 2020; Accepted: 17 February 2020; Published: 21 February 2020 Abstract: Urolithin A is a metabolite generated from ellagic acid and ellagitannins by the intestinal microbiota after consumption of fruits such as pomegranates or strawberries. The objective of this study was to determine the cytoprotective capacity of this polyphenol in Neuro-2a cells subjected to oxidative stress, as well as its direct radical scavenging activity and properties as an inhibitor of oxidases. Cells treated with this compound and H2O2 showed a greater response to oxidative stress than cells only treated with H2O2, as mitochondrial activity (MTT assay), redox state (ROS formation, lipid peroxidation), and the activity of antioxidant enzymes (CAT: catalase, SOD: superoxide dismutase, GR: glutathione reductase, GPx: glutathione peroxidase) were significantly ameliorated; additionally, urolithin A enhanced the expression of cytoprotective peroxiredoxins 1 and 3. Urolithin A also acted as a direct radical scavenger, showing values of 13.2 µM Trolox Equivalents for Oxygen Radical Absorbance Capacity (ORAC) and 5.01 µM and 152.66 µM IC50 values for superoxide and 2,2-diphenyss1-picrylhydrazyl (DPPH) radicals, respectively.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0208890 A1 Gousse Et Al
    US 20120208890A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0208890 A1 Gousse et al. (43) Pub. Date: Aug. 16, 2012 (54) STABLE HYDROGEL COMPOSITIONS of application No. 127956,542, filed on Nov.30, 2010, INCLUDING ADDITIVES which is a continuation-in-part of application No. 12/714,377, filed on Feb.26, 2010, which is a continu (75) Inventors: Cecile Gousse, Dingy Saint Clair ation-in-part of application No. 12/687,048, filed on (FR); Pierre F. Lebreton, Annecy Jan. 13, 2010. (FR); Nicolas Prost, Mornant (FR): Sumit Paliwal, Goleta, CA (US); Publication Classification Dennis Van Epps, Goleta, CA (US) (51) Int. C. (73) Assignee: ALLERGAN, INC. Irvine, CA A6IR 8/4I (2006.01) (US) A61O 19/08 (2006.01) A6IR 8/42 (2006.01) (21) Appl. No.: 13/350,518 (52) U.S. Cl. ......................................... 514/626; 514/653 (22) Filed: Jan. 13, 2012 (57) ABSTRACT Related U.S. Application Data The present specification generally relates to hydrogel com (63) Continuation-in-part of application No. 13/005,860, positions and methods of treating a soft tissue condition using filed on Jan. 13, 2011, which is a continuation-in-part Such hydrogel compositions. Patent Application Publication Aug. 16, 2012 Sheet 1 of 7 US 2012/0208890 A1 lication Publication ug. 16, 2012 Sheet 2 of 7 co & S. N SESo 9 CD s Y NI C O O CN ve ve D an an 5 S. 5 3. 9. S. Patent Application Publication Aug. 16, 2012 Sheet 3 of 7 US 2012/0208890 A1 00Z?000).00800900700Z0 O.GZ?eSÅep~ Patent Application Publication Aug.
    [Show full text]